QUOTED. 22 February 2021. Alex Gorsky.
The four major orthopedic companies have seen significant reductions in fourth-quarter revenues due to the delay of elective procedures amid the resurgence of COVID-19 cases. See what Johnson & Johnson’s CEO Alex Gorsky said about it here.
“The knee market was perhaps hit more than others, just because many of those procedures can be delayed perhaps versus a hip procedure. But we would expect that to return over the course of this year, as we see the pandemic dealt with in a more effective way and things hopefully return to a more normal state.” – Alex Gorsky, CEO, Johnson & Johnson
- Find out more: Orthopedic Roundup Q4: S&N, Stryker, J&J, Zimmer Biomet See Pandemic-Related Sales Impact
Click here for a free trial of Medtech Insight